Pharma stocks have surged due to a 'Patent Cliff,' where numerous drug patents expire, allowing generic manufacturers, especially in India, to produce cheaper versions. This trend is causing a revenue drop for original drug makers but presents growth opportunities for Indian pharma companies, reflected in the Nifty Pharma index's recent performance.
